National Guideline Clearinghouse | Bortezomib in multiple myeloma and lymphoma.
Program in Evidence-based Care ► Cancer Care Ontario (CCO)
February 10, 2014
Guideline Title
Bortezomib in multiple myeloma and lymphoma.
Bibliographic Source(s)
| Kouroukis CT, Reece D, Baldassarre FG, Haynes AE, Imrie K, Cheung M, Hematology Disease Site Group. Bortezomib in multiple myeloma and lymphoma. Toronto (ON): Cancer Care Ontario (CCO); 2013 Mar 18. 209 p. (Evidence-based series; no. 6-18). [293 references] |
Guideline Status
This is the current release of the guideline.
This guideline updates a previous version: Reece D, Kouroukis T, Haynes AE, Imrie K. Bortezomib in multiple myeloma and lymphoma. Toronto (ON): Cancer Care Ontario (CCO); 2008 Nov 24. 41 p. (CED-CCO special advice report; no. 11).
The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from their reviewing and updating activities.
Please visit the Cancer Care Ontario Web site 
for details on any new evidence that has emerged and implications to the guidelines.
https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34323 for details on any new evidence that has emerged and implications to the guidelines.
.png)
No hay comentarios:
Publicar un comentario